Project Grant R21CA312961
Award Date 6/15/26
Completion Date 5/31/28
Dollars Obligated $434K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02111, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded Harvard Medical School a $237,023 Project Grant under the Cancer Biology Research program (CFDA 93.396) on March 13, 2026, with completion scheduled for February 28, 2029. The grant funds development of high-throughput technological tools to track the fate of prematurely terminated transcripts in cancer cells, specifically focusing on alternative polyadenylation (APA) events. The research addresses a critical gap in...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...
- Federal Grant Award Summary Oregon Health & Science University (OHSU) received a $1,042,004 Project Grant award from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396), effective March 26, 2026, with completion targeted for February 28, 2031. The award supports the development and utilization of an innovative microphysiological bone metastasis-on-a-chip platform to advance understanding of prostate cancer metastasis to bone, which occurs in over 80% of...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $186,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) on June 23, 2025, with a completion date of May 31, 2027. The award supports pilot and feasibility studies for NN-01-195, a novel tumor-targeted Aurora-A kinase (AURKA) inhibitor developed through a drug conjugate approach. The research involves preclinical evaluation of this chimeric compound, which fuses an...
- Federal Project Grant Award Summary Duke University's Office of Research Administration received a $179,276 Project Grant award from the National Cancer Institute (NCI) under the Cancer Research Manpower program (CFDA 93.398) on December 1, 2025, with a completion date of May 31, 2027. The award supports research investigating the role of the ABL kinase-regulated HIF-1A-TAZ signaling pathway in promoting brain metastasis in triple-negative breast cancer (TNBC). The project deliverables include...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Trustees of Columbia University in the City of New York a Project Grant of $531,825 under the Cancer Biology Research program (CFDA 93.396) effective August 1, 2025, with completion targeted for July 31, 2030. This research initiative focuses on understanding the molecular mechanisms of castration sensitivity in prostate epithelium, with the ultimate goal of improving therapeutic responses to androgen-deprivation therapy...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of Toledo Health Science Campus Division a Project Grant totaling $418,822 under the Cancer Treatment Research program (CFDA 93.395) for the period May 1, 2026 through April 30, 2028. This award supports the development and preclinical evaluation of novel selective allosteric modulators (PITT molecules) targeting the parathyroid hormone receptor type 1 (PTH1R) to inhibit prostate cancer bone metastases. The...
- Federal Project Grant Award Summary The National Cancer Institute awarded a $585,482 Project Grant under the Cancer Biology Research program (CFDA 93.396) to New York University School of Medicine for a five-year research initiative spanning June 1, 2026, through May 31, 2031. This award supports fundamental research investigating the role of the translation factor DAP5 in selective messenger RNA (mRNA) translation and m6A mRNA methylation as mechanisms driving breast cancer metastasis. The...
- Federal Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $1.365 million Project Grant under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031, to conduct fundamental research on the role of ATAD2 (ATPase Family AAA Domain-Containing Protein 2) in prostate cancer progression and metastasis. The research will employ immunocompetent mouse and human prostate cancer models to determine the functional...
- Federal Grant Award Summary The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $1,467,021 under the Cancer Treatment Research program (CFDA 93.395) for a five-year project running from April 1, 2026 through March 31, 2031. This project focuses on identifying and targeting tumor regenerative cells (TRCs) that drive treatment resistance and metastatic recurrence in locally advanced rectal cancer (LARC) patients undergoing total neoadjuvant therapy (TNT). Through...